Policy
And Advocacy

To advance our goal of improving the lives of people affected by psoriasis and psoriatic arthritis in Canada, CPN is committed to providing input through government and other relevant consultations on issues that matter to our community. Thank you to everyone who helps to inform our submissions by responding to CPN surveys.

2022

biosimilars policy 2022

Consultation on building the future of clinical trials at CIHR

November 2022

biosimilars policy 2022

Joint feedback on Health Canada's consultation regarding a handbook for healthcare professionals on biosimilar biologic drugs

May 2022

biosimilars policy 2022

Brief on Bill C-22, An Act to reduce poverty and to support the financial security of persons with disabilities by establishing the Canada disability benefit and making a consequential amendment to the Income Tax Act

November 2022

2021

Disability Inclusion Action Plan consultation

Disability Inclusion Action Plan joint submission by CPN and CAPP

September 2021

CADTH Feedback on Scoping Document: Utilization of Biologic Disease-Modifying Antirheumatic Drugs for Plaque Psoriasis

CADTH Feedback on Scoping Document: Utilization of Biologic Disease-Modifying Antirheumatic Drugs for Plaque Psoriasis

August 2021

CADTH Feedback on Scoping Document Formulary Management of Biologics in Plaque Psoriasis

CADTH Feedback on Scoping Document: Formulary Management of Biologics in Plaque Psoriasis

2021

2020

2019